VIRONIKA LLC
Biotech · Private
Small molecule inhibitor of Epstein-Barr Virus ZTA protein
vironika.com →- Grants
- $4.0M
- 12 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20142016201820202022
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Stable and Tunable Episomes for Gene Therapy | $130,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Small Molecule Inhibitor for EBV Latent Infection | $750,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a Small Molecule Inhibitor for EBV Lytic Reactivation | $300,001 | |
| Federal grant | Department of Health and Human Services · Phase I · Small Molecule Targeting of Viral Non-Coding RNA EBER1 to Detect and Treat Latent EBV | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Small Molecule Targeting of Viral Non-Coding RNA EBER1 to Detect and Treat Latent EBV | $600,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Small Molecule Targeting of Viral Non-Coding RNA EBER1 to Detect and Treat Latent EBV | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a Small Molecule Inhibitor to Eradicate HSV Latent Infection in Neurons | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a Small Molecule Inhibitor to Eradicate HSV Latent Infection in Neurons | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeting HIV transcription with RNA-binding small molecules | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeting HIV transcription with RNA-binding small molecules | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Discovery of inhibitors of EBV lytic cycle inducing protein ZTA for therapeutic development | $269,073 | |
| Federal grant | Department of Health and Human Services · Phase I · Discovery of inhibitors of EBV lytic cycle inducing protein ZTA for therapeutic development | $130,205 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3043 | AIVOCODE, INC. | — | — |
| 3044 | Panorama Research Incorporated | — | — |
| 3045 | E&E BIOCLUB LLC | — | — |
| 3046 | VIRONIKA LLC | — | — |
| 3047 | CASCADE THERAPEUTICS, INC. | — | — |
| 3048 | BACCHUS THERAPEUTICS INC | — | — |
| 3049 | INFINITESIMAL, LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.